Qsymia is the only once-daily combination pill proven to significantly reduce weight1-5
- Qsymia was studied in 2 large trials supporting FDA approval that involved 3754 patients whose BMI was 30 kg/m2 or greater, or 27 kg/m2 or greater with 2 or more weight-related comorbidities such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Patients were randomized to placebo, phentermine 3.75 mg/topiramate 23 mg, phentermine 7.5 mg/topiramate 46 mg, or phentermine 15 mg/topiramate 92 mg. In these trials, it was recommended that patients eat a well-balanced diet and reduce their caloric intake by 500 kcal/day. Your patients’ results may vary depending on their BMI, diet, activity, dose of Qsymia, and other factors1,2
- In a subset analysis, patients with a BMI ≥30 kg/m2 taking the recommended dose of Qsymia (n=2076) lost an average of approximately 10% of their body weight, 4 inches off their waist, and 24 pounds after 1 year2
Qsymia can help you treat many of the patients you see in your practice1,2
Review the range of overweight and obese patient evaluted in clinical studies. Click on a patient type to view more data.
Patient Type 1: Comorbid
Absolute Weight Reduction After 1 Year in Patients With a Baseline BMI of 30 kg/m2 1,2
‡Statistical significance achieved (type 2 diabetes: P=.0115; hypertension: P<.0001; P values are from Fisher’s exact test).2 Qsymia is not indicated for the treatment of type 2 diabetes, hypertension, dyslipidemia, or depression.1
Patient Type 2: BMI Range
Percentage of Weight Reduction by BMI After 1 Year1,2
Patient Type 3: Difficult to Treat
Absolute Weight Reduction Across Patient Segments With a BMI 30 kg/m2 After 1 Year1,2
*Qsymia is contraindicated for hyperthyroidism.1
† General dose selection should be cautious, starting with lowest dose.1
‡ LS=least squares.
§ P<.0001 vs placebo.
Qsymia has been proven effective in obese patients with metabolic challenges that cause weight gain, increased abdominal fat, and/or diffculty losing weight. Included in clinical studies were a variety of diffcult-to-treat patients such as those who were menopausal, postmenopausal, aged 50 years or older, or suffering from hypothyroidism.2,6-10